Качественная клиническая практика (Oct 2020)

Rationale for use mefloquine for COVID-19 treatment

  • V. A. Otdelenov,
  • K. B. Mirzaev,
  • A. V. Dmitriev,
  • V. V. Poroikov,
  • D. A. Sychev

DOI
https://doi.org/10.37489/2588-0519-2020-S4-103-105
Journal volume & issue
Vol. 0, no. 4S
pp. 103 – 105

Abstract

Read online

Currently, the use of mefloquine in patients with COVID-19 does not have sufficient scientific justification and, given the unfavorable efficacy and safety profile, cannot be considered for routine use in clinical practice.

Keywords